zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressantit - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
kenacort-t 0.1 % pasta suuonteloon
bristol-myers squibb ab - triamcinoloni acetonidum - pasta suuonteloon - 0.1 % - triamsinoloni
kenacort-t comp liuos iholle
bristol-myers squibb ab - benzalkonii chloridum,triamcinoloni acetonidum,happo salicylicum - liuos iholle - triamsinoloni
mycostatin 500000 iu tabletti
bristol-myers squibb ab - nystatinum - tabletti - 500000 iu - nystatiini
vivin c 200 poretabletti
bristol-myers squibb - happo ascorbicum,happo acetylsalicylicum - poretabletti - asetyylisalisyylihappo, yhdistelmävalmisteet
siqualone 1 mg tabletti, päällystetty
bristol-myers squibb ab - fluphenazini hydrochloridum - tabletti, päällystetty - 1 mg - flufenatsiini
siqualone 5 mg tabletti, päällystetty
bristol-myers squibb ab - fluphenazini hydrochloridum - tabletti, päällystetty - 5 mg - flufenatsiini
fungizone 10 mg imeskelytabletti
bristol-myers squibb ab - amphotericinum b - imeskelytabletti - 10 mg - amfoterisiini
mycostatin 100000 iu/ml oraalisuspensio
bristol-myers squibb ab - nystatinum - oraalisuspensio - 100000 iu/ml - nystatiini
velosef 500 mg kapseli
bristol-myers squibb gmbh - cefradinum - kapseli - 500 mg - kefradiini